ORCHPHARMAOrchid Pharma Ltd.

    Orchid Pharma Q2 FY27 Results: Consolidated Net Profit ₹28.59 Crore on Total Income of ₹359 Crore

    • Earnings
    • pharmaceuticals
    A pile of assorted tablets and capsules
    Illustrative image. Photo: Pixabay, via Wikimedia Commons (CC0)

    Orchid Pharma (NSE: ORCHPHARMA) reported consolidated total income of ₹359.02 crore and net profit of ₹28.59 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹369.90 crore and net profit of ₹36.76 crore, it said in a filing on 14 Nov 2026.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹359.02 crore, up 15.8% YoY and 17.3% QoQ
    • Net profit and EPS: ₹28.59 crore; basic EPS ₹4.77, against a loss of ₹0.90 crore a year earlier
    • Other income: ₹17.76 crore, up 52.6% YoY, 4.9% of total income

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹369.90 crore, up 17.5% YoY and 17.7% QoQ
    • Net profit and EPS: ₹36.76 crore; basic EPS ₹6.14, against ₹6.91 crore and ₹1.15 a year earlier
    • Other income: ₹28.63 crore, up 75.8% YoY, 7.7% of total income

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    359.02310.10+15.8%306.00+17.3%
    28.59-0.90n/a3.22+786.8%
    EPS, basic (₹)4.77-0.15n/a0.54+783.3%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Consolidated net profit rose to ₹28.59 crore from a loss of ₹0.90 crore a year earlier, while revenue from operations grew 14.3% to ₹341.27 crore. Other income of ₹17.76 crore, up 52.6%, accounts for about two-thirds of the ₹26.84 crore profit before tax, so a large part of the profit sits outside core revenue.

    The consolidated tax line is a credit of ₹0.04 crore, and the filing gives no reason for it. Finance costs of ₹3.64 crore are 1.0% of total income, up 41.9% YoY.

    The company says it will account for any additional impact once Central and State Rules are finalised; the Rules are not yet notified.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    369.90314.75+17.5%314.22+17.7%
    36.766.91+432.1%11.94+207.9%
    EPS, basic (₹)6.141.15+433.9%1.99+208.5%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Revenue from operations rose 14.3%, while other income rose 75.8% to ₹28.63 crore, which is 77.9% of profit before tax.

    Standalone net profit is ₹8.17 crore higher than the consolidated figure.

    Inference

    The filing states that the Scheme of Amalgamation with Dhanuka Laboratories Limited became effective on 10 Jul 2026 with an appointed date of 1 Apr 2024, and that results are restated from that date. The Synmedic Laboratories business was transferred by slump sale effective 3 Jul 2026.

    The filing says the net proceeds of ₹391.80 crore from the QIP raised on 27 Jun 2023 have been fully utilised. It does not say whether the Synmedic transfer consideration has been paid or what amount was paid, and it does not give the reason for the consolidated tax credit.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts